Inclusion criteria:

   1. Adult 18-72 years

   2. Cirrhosis: defined by stage 4 on biopsy or noninvasive tests or presence of
   splenomegaly and platelet of 130K or lower, or presence of shrunken nodular liver on
   CT or MRI, or presence of varices or encephalopathy or ascites.

   3. HCV genotype 1 or indeterminate and later assessed at Screening and confirmed as
   genotype 1

Exclusion criteria:

   1. Uncontrolled ascites, uncontrolled hepatic encephalopathy, or uncontrolled
   esophageal/gastric varices

   2. Co-infection with HIV or hepatitis B (HBV)

   3. CPT 7 or above, or MELD >10

   4. Total bilirubin 4.0 mg/dL or above

   5. CrCl (creatinine clearance) < 30 mL/min

   6. Any unstable active medical illnesses.

   7. Active use of illicit substances, alcohol, or smoking.

   8. Any malignancy within last 5 years except for basal cell skin cancer that has been
   adequately treated or HCC within Milan or UCSF criteria, which will be acceptable

   9. Any prior treatment with direct acting antivirals (approved or investigational),
   including HCV protease inhibitors, such as SMV. Patients who received prior treatment
   with SOF, and/or NS5A inhibitors (e.g. ledipasvir or Daclatasvir) can be included in
   this study

10. Platelet < 30 K/uL